Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for my updated look at REGN.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years. Learn more on REGN stock here.

See the latest Regeneron Pharmaceuticals Inc stock price (REGN:XNAS), related news, ... Stock XNAS Rating as of Jul 11, 2025. Read Company Report Download PDF. More Actions ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, ...

Regeneron’s stock has experienced a significant decline, dropping 55% since its peak in August 2024, while the S&P 500 index has risen by 5% during the same period.

On Friday, RBC Capital Markets downgraded Regeneron (NASDAQ: REGN) Pharmaceuticals’ shares, moving the rating from Outperform to Sector Perform.The firm also significantly reduced the price ...

On Wednesday, TD Cowen adjusted its outlook on Regeneron Pharmaceuticals, with analyst Tyler Van Buren revising the price target to $1,030 from the previous $1,230. Despite the reduction, the firm ...

This was the stock's fourth consecutive day of gains.

Investing.com - TD Cowen has reiterated a Buy rating and $800.00 price target on Regeneron Pharmaceuticals (NASDAQ: REGN), a prominent biotech player with a $58.1 billion market cap, following FDA ...

REGN stock dropped 57.9% from a high of $28.60 on 2 May 2007 to $12.05 on 11 March 2009, in comparison to a peak-to-trough fall of 56.8% for the S&P 500; ...